TOG Review (RCOG Journal)

MRCOG Part 2

Maternal Medicine

The role of thrombophilia testing in women with adverse pregnancy outcomes

Key Statistics

  • 15% — Pregnancies with placenta-mediated complications
  • £250.82 — Cost of full thrombophilia screen (NHS)
  • ~40% — Women with heparin adverse effects

Don't-miss facts

  1. Do not routinely test for inherited thrombophilia after RPL, FGR, severe PET, abruption or stillbirth — results do not alter management (SMFM Choosing Wisely 2016)

  2. TIPPS: dalteparin no benefit (17.1% vs 18.9%), more minor bleeding (19.6% vs 9.2%)

  3. ALIFE & SPIN: aspirin ± LMWH does not improve live birth in unexplained RPL; ALIFE live birth highest in placebo arm

  4. Aspirin is the evidence-based intervention: 100–150 mg nocte, before 16 weeks — ↓severe PET 17%, ↓FGR 10%

  5. LMWH still indicated for: APS antibodies, previous catastrophic APS, previous VTE — with haematology input

  6. APS diagnosis needs positive serology on 2 occasions ≥12 weeks apart; first-line obstetric APS treatment = low-dose aspirin

  7. Catastrophic APS: <1% of APS, 50% mortality — anticoagulation + high-dose steroids + plasma exchange

  8. ~80% of women with RPL have a successful next pregnancy regardless of treatment (HepASA) — use this when counselling

Trial verdicts at a glance

Negative for LMWH: ALIFE · SPIN · HABENOX · HepASA · HAPPY · TIPPS · HEPEPE · Farquharson

Positive/partial: Gris 2004 · Rey 2009 · Kupferminc 2011 · FRUIT (<34 weeks only, NNT 12) Awaited: ALIFE2 (target 776)

Abbreviation Key

  • FVL — factor V Leiden mutation
  • FDIU — intrauterine fetal death
  • APC — activated protein C
  • SGA — small for gestational age
  • APL — antiphospholipid (antibodies)
  • VTE — venous thromboembolism
  • APS — antiphospholipid syndrome
  • NNT — number needed to treat
  • LMWH — low-molecular-weight heparin
  • OR / RR — odds ratio / risk ratio
  • RPL — recurrent pregnancy loss
  • ESHRE — European Society of Human Reproduction and Embryology
  • FGR — fetal growth restriction
  • SMFM — Society for Maternal and Fetal Medicine
  • PET — severe pre-eclampsia

Source: Unterscheider J, Kane SC, Cutts B, Savoia H, Said JM. The role of thrombophilia testing in women with adverse pregnancy outcomes. The Obstetrician & Gynaecologist 2017;19:163–72. doi:10.1111/tog.12366

MRCOG AI is an independent educational tool. It is not affiliated with, endorsed by, or connected to the Royal College of Obstetricians and Gynaecologists (RCOG).

Included with a Pass Package

  • Audio overview of this guideline
  • Practice questions drawn from it
  • AI tutor answers grounded in its text
  • Your own annotations
Start free